Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients
BackgroundWidespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent F...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1530438/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540311373479936 |
|---|---|
| author | Ileana Maria Vodă Vlad Eugen Tiu Vlad Eugen Tiu Luiza Răuță Paul Ciucur Andreea Ioana Mușuroi Alina Flavia Tomescu Alina Flavia Tomescu Nicoleta Laura Humă Florin Dobrițoiu Florin Dobrițoiu Elena Terecoasă Elena Terecoasă Lucian Negreanu Lucian Negreanu Cristina Tiu Cristina Tiu |
| author_facet | Ileana Maria Vodă Vlad Eugen Tiu Vlad Eugen Tiu Luiza Răuță Paul Ciucur Andreea Ioana Mușuroi Alina Flavia Tomescu Alina Flavia Tomescu Nicoleta Laura Humă Florin Dobrițoiu Florin Dobrițoiu Elena Terecoasă Elena Terecoasă Lucian Negreanu Lucian Negreanu Cristina Tiu Cristina Tiu |
| author_sort | Ileana Maria Vodă |
| collection | DOAJ |
| description | BackgroundWidespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.MethodsWe present a critical review of the available literature on diagnosis and management of anti-CD20 induced colitis and display a case series of 3 suspected patients in our cohort.ResultsTwo patients met the full criteria for ocrelizumab-induced colitis, while a third partially met the criteria. Following symptomatic treatment and discontinuation of ocrelizumab, the patients showed favorable outcomes.ConclusionOcrelizumab-induced colitis is a rare, but severe adverse event. Its incidence may be higher than expected, reaching 1,95% in our cohort of MS patients. Further reporting of such cases is essential to broaden our understanding of this side effect. |
| format | Article |
| id | doaj-art-39e365dc347443ec8260f204e59efd93 |
| institution | Kabale University |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-39e365dc347443ec8260f204e59efd932025-02-05T05:17:38ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-02-011610.3389/fneur.2025.15304381530438Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patientsIleana Maria Vodă0Vlad Eugen Tiu1Vlad Eugen Tiu2Luiza Răuță3Paul Ciucur4Andreea Ioana Mușuroi5Alina Flavia Tomescu6Alina Flavia Tomescu7Nicoleta Laura Humă8Florin Dobrițoiu9Florin Dobrițoiu10Elena Terecoasă11Elena Terecoasă12Lucian Negreanu13Lucian Negreanu14Cristina Tiu15Cristina Tiu16Bucharest University Emergency Hospital, Bucharest, RomaniaElias University Emergency Hospital, Bucharest, RomaniaClinical Neurosciences, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaInternal Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaPathoteam Diagnostic Laboratory, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaClinical Neurosciences, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaInternal Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaClinical Neurosciences, Carol Davila University of Medicine and Pharmacy, Bucharest, RomaniaBackgroundWidespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.MethodsWe present a critical review of the available literature on diagnosis and management of anti-CD20 induced colitis and display a case series of 3 suspected patients in our cohort.ResultsTwo patients met the full criteria for ocrelizumab-induced colitis, while a third partially met the criteria. Following symptomatic treatment and discontinuation of ocrelizumab, the patients showed favorable outcomes.ConclusionOcrelizumab-induced colitis is a rare, but severe adverse event. Its incidence may be higher than expected, reaching 1,95% in our cohort of MS patients. Further reporting of such cases is essential to broaden our understanding of this side effect.https://www.frontiersin.org/articles/10.3389/fneur.2025.1530438/fullmultiple sclerosisdrug induced colitiscolitisocrelizumabreviewCD-20 |
| spellingShingle | Ileana Maria Vodă Vlad Eugen Tiu Vlad Eugen Tiu Luiza Răuță Paul Ciucur Andreea Ioana Mușuroi Alina Flavia Tomescu Alina Flavia Tomescu Nicoleta Laura Humă Florin Dobrițoiu Florin Dobrițoiu Elena Terecoasă Elena Terecoasă Lucian Negreanu Lucian Negreanu Cristina Tiu Cristina Tiu Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients Frontiers in Neurology multiple sclerosis drug induced colitis colitis ocrelizumab review CD-20 |
| title | Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients |
| title_full | Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients |
| title_fullStr | Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients |
| title_full_unstemmed | Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients |
| title_short | Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients |
| title_sort | ocrelizumab induced colitis critical review and case series from a romanian cohort of ms patients |
| topic | multiple sclerosis drug induced colitis colitis ocrelizumab review CD-20 |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1530438/full |
| work_keys_str_mv | AT ileanamariavoda ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT vladeugentiu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT vladeugentiu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT luizarauta ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT paulciucur ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT andreeaioanamusuroi ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT alinaflaviatomescu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT alinaflaviatomescu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT nicoletalaurahuma ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT florindobritoiu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT florindobritoiu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT elenaterecoasa ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT elenaterecoasa ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT luciannegreanu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT luciannegreanu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT cristinatiu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients AT cristinatiu ocrelizumabinducedcolitiscriticalreviewandcaseseriesfromaromaniancohortofmspatients |